ShanXi C&Y Pharmaceutical GroupLTD Dividends and Buybacks
Dividend criteria checks 0/6
ShanXi C&Y Pharmaceutical GroupLTD does not currently pay a dividend.
Key information
0%
Dividend yield
-1.5%
Buyback Yield
Total Shareholder Yield | -1.5% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | CN¥0.020 |
Payout ratio | 0% |
Recent dividend and buyback updates
No updates
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if 300254's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 300254's dividend payments have been increasing.
Dividend Yield vs Market
ShanXi C&Y Pharmaceutical GroupLTD Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (300254) | 0% |
Market Bottom 25% (CN) | 0.6% |
Market Top 25% (CN) | 2.2% |
Industry Average (Pharmaceuticals) | 1.7% |
Analyst forecast (300254) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate 300254's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 300254's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: 300254 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 300254 has not reported any payouts.